Weybosset Research & Management LLC Has $510,000 Position in Biohaven Ltd. (NYSE:BHVN)

Weybosset Research & Management LLC lifted its holdings in Biohaven Ltd. (NYSE:BHVN) by 23.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,645 shares of the company’s stock after buying an additional 2,635 shares during the period. Biohaven comprises approximately 0.2% of Weybosset Research & Management LLC’s portfolio, making the stock its 29th biggest position. Weybosset Research & Management LLC’s holdings in Biohaven were worth $510,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Farallon Capital Management LLC grew its stake in shares of Biohaven by 181.4% in the 2nd quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock valued at $78,028,000 after buying an additional 1,449,000 shares in the last quarter. Point72 Asset Management L.P. grew its position in Biohaven by 745.9% in the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company’s stock worth $74,969,000 after acquiring an additional 1,322,922 shares in the last quarter. Armistice Capital LLC increased its stake in shares of Biohaven by 74.8% during the 2nd quarter. Armistice Capital LLC now owns 1,396,968 shares of the company’s stock worth $48,489,000 after purchasing an additional 597,705 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Biohaven by 563.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company’s stock valued at $25,416,000 after purchasing an additional 431,954 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Biohaven by 85.4% in the third quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock worth $40,448,000 after purchasing an additional 372,737 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Trading Down 2.5 %

NYSE:BHVN traded down $0.97 during mid-day trading on Friday, hitting $38.20. The company’s stock had a trading volume of 718,139 shares, compared to its average volume of 908,545. The company has a market capitalization of $3.86 billion, a price-to-earnings ratio of -4.09 and a beta of 1.29. Biohaven Ltd. has a fifty-two week low of $26.80 and a fifty-two week high of $62.21. The stock has a fifty day moving average of $43.19 and a 200-day moving average of $42.19.

Biohaven (NYSE:BHVN) last posted its earnings results on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.03). On average, equities analysts anticipate that Biohaven Ltd. will post -8.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BHVN has been the topic of several recent research reports. Leerink Partners raised their target price on Biohaven from $55.00 to $60.00 and gave the company an “outperform” rating in a report on Monday, September 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 target price (up previously from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. Bank of America upped their price objective on shares of Biohaven from $52.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Finally, TD Cowen lifted their target price on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Thirteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $63.00.

Insider Activity

In other Biohaven news, Director John W. Childs bought 29,000 shares of the stock in a transaction dated Monday, December 30th. The stock was bought at an average cost of $35.94 per share, for a total transaction of $1,042,260.00. Following the completion of the purchase, the director now owns 2,368,741 shares in the company, valued at $85,132,551.54. This represents a 1.24 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 16.00% of the stock is owned by corporate insiders.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.